Related Experiment Videos
Optimizing the treatment of heart failure
1Cardiovascular Research Laboratory, Louisiana State University Medical School, New Orleans 70112.
Current Opinion in Cardiology
|July 1, 1994
Summary
Angiotensin converting enzyme (ACE) inhibitors improve survival and symptoms in patients with heart failure, from mild to advanced stages. Despite proven benefits, uptake remains low, but fears of adverse effects are unfounded.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Background:
- Heart failure management has evolved with new and re-evaluated drugs.
- Key drug classes include ACE inhibitors, digitalis, diuretics, and nitrates/hydralazine combinations.
Purpose of the Study:
- To summarize the evidence supporting the use of ACE inhibitors in heart failure management.
- To address concerns regarding ACE inhibitor use and highlight their benefits across different heart failure severities.
Main Methods:
- Review of major clinical trials including CONSENSUS I, V-HeFT II, SOLVD, Munich Heart Failure trial, ISIS 4, and GISSI 3.
- Analysis of data from large clinical registries on ACE inhibitor prescription rates.
Main Results:
- ACE inhibitors are recommended for severe/advanced heart failure (with digitalis and diuretics) and mild heart failure.
- Despite proven benefits, only 40% of heart failure patients receive ACE inhibitors, often due to unfounded fears of renal damage or hypotension.
- ACE inhibitors also benefit patients with anterior myocardial infarcts and reduced left ventricular function, and improve survival in acute myocardial infarction.
Conclusions:
- ACE inhibitors are crucial for improving symptoms and survival in various stages of heart failure and post-myocardial infarction.
- Treatment optimization involves identifying etiology, restricting sodium, and utilizing ACE inhibitors for depressed left ventricular function, including NYHA class I.
- Fears regarding ACE inhibitor side effects are unfounded and should not limit their use.